EP2419438B1 - Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung - Google Patents

Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung Download PDF

Info

Publication number
EP2419438B1
EP2419438B1 EP10718238.8A EP10718238A EP2419438B1 EP 2419438 B1 EP2419438 B1 EP 2419438B1 EP 10718238 A EP10718238 A EP 10718238A EP 2419438 B1 EP2419438 B1 EP 2419438B1
Authority
EP
European Patent Office
Prior art keywords
peptide
hydrolyzate
gly
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10718238.8A
Other languages
English (en)
French (fr)
Other versions
EP2419438A1 (de
Inventor
Claude Dal Farra
Nouha Domloge
Jean-Marie Botto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISP Investments LLC
Original Assignee
ISP Investments LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISP Investments LLC filed Critical ISP Investments LLC
Publication of EP2419438A1 publication Critical patent/EP2419438A1/de
Application granted granted Critical
Publication of EP2419438B1 publication Critical patent/EP2419438B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/06—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/10—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention is in the cosmetic and pharmaceutical field, and more particularly in the field of dermatology.
  • the invention relates to a peptide hydrolyzate enriched with bioactive peptide, capable of reinforcing the cutaneous barrier function and of stimulating epidermal differentiation.
  • the bioactive peptide is characterized in that it comprises from 4 to 6 amino acids including at least one glycine residue, a leucine residue and a glutamic acid residue and having a sequence of general formula (I) X 1 - [Gly, Glu, Leu] -X 2 -X 3 selected from the sequences SEQ ID No. 1 to SEQ ID No.
  • the invention also relates to a composition comprising, in a physiologically acceptable medium, a peptide hydrolyzate enriched in bioactive peptide as an active ingredient capable of reinforcing the barrier function of the epidermis.
  • a pharmaceutical composition comprising this new active ingredient as a medicament.
  • the invention finally relates to the cosmetic use of said peptide hydrolyzate, as an active ingredient for activating HMG-CoA reductase and thus reinforcing the cutaneous barrier function and stimulating epidermal differentiation.
  • the invention also relates to a cosmetic treatment method for preventing and / or combating external aggressions and the manifestations of skin aging.
  • the primary function of the epidermis is to provide a barrier between the external environment and the internal environment. It is the outermost layer of the epidermis, the stratum corneum, which provides this function. It is composed of keratinocytes at the final stage of their differentiation, the corneocytes, sealed to each other by a thick intercellular cement, both flexible and impermeable. Thus, in the stratum corneum, there is a cell compartment consisting of corneocytes and an extracellular compartment consisting mainly of lipids, organized into multilamellar structures.
  • the lipid content of the human stratum corneum is estimated to be 15% cholesterol ester, 16% long-chain saturated free fatty acids, 32% cholesterol, % of ceramides, although the inter-individual variations are quite large ( Norlen L. et al. J. Invest. Dermatol. 1999; 112 (1) p. 72-77 ).
  • These lipids are synthesized by the keratinocytes of the intermediate layers of the epidermis, and secreted in specialized organelles called "lamellar bodies" or Odland bodies.
  • the epidermis is a very active site for the synthesis of cholesterol.
  • HMG-CoA reductase 3-hydroxy-3-methylglutaryl-Coenzyme A
  • This step is catalyzed by a membrane enzyme called HMG-CoA reductase (EC 1.1.1.34).
  • HMG-CoA reductase EC 1.1.1.34
  • Sequencing data from the human genome show that there are at least 2 isoforms of HMG-CoA reductase, encoded by a single gene, located on chromosome 5 ( Luskey et al., J Biol Chem., 1985 260 (18), p.10271-7 ).
  • statins for inhibiting HMG-CoA reductase
  • statins for inhibiting HMG-CoA reductase
  • This inhibitory effect of statins is also manifested in human skin. Indeed, experimental administration of statins topically disrupts the barrier function of the skin ( Proksch E. et al., British J. Dermatol., 1993, (128), p. 473-482 ).
  • a peptide hydrolyzate enriched in bioactive peptide according to the invention may have advantageous properties for reinforcing the skin barrier function and for stimulating epidermal differentiation. It is also possible to improve by this action certain pathological dysfunctions related to the barrier function (hypersensitive, irritated, or reactive skin, atopic eczema).
  • bioactive peptides The inventors have in fact demonstrated a cosmetic and therapeutic, especially dermatological, activity of peptide hydrolysates containing certain particular peptides, hereinafter called bioactive peptides.
  • the peptide hydrolyzate, enriched in bioactive peptide when applied to the skin, reinforces the barrier function of the epidermis and stimulates epidermal differentiation. These properties have been demonstrated by better protection of the cutaneous tissue with respect to external aggressions and an increase in the production of lipids constituting the stratum corneum.
  • bioactive peptide means a sequence of at least four amino acids, linked together by peptide bonds or by modified peptide bonds and which has an in vivo or in vitro activity characteristic of the activity of the active ingredient according to the invention.
  • the characteristic biological activity according to the invention is defined in vitro by the ability of the peptide to activate HMG-CoA reductase, either by increasing the protein synthesis of HMG-CoA reductase (by direct or indirect modulation of the gene expression of HMG-CoA reductase), either by increasing the enzymatic activity of HMG-CoA reductase, or by other biological processes such as the stabilization of the HMG-CoA reductase protein or stabilization messenger RNA transcripts.
  • skin all the covering tissues constituting the skin and the mucous membranes, including the integuments (hair, eyelashes, hairs, eyebrows).
  • peptide hydrolyzate is intended to mean a mixture of compounds predominantly represented by peptides or oligopeptides. According to the invention, the terms “peptide hydrolyzate” or “active principle” will be used interchangeably.
  • peptide-like compounds means the protein fragments, the peptides and the free amino acids present in the peptide hydrolyzate according to the invention.
  • topical application the application or spreading of the active ingredient according to the invention, or a composition containing it, on the surface of the skin or mucosa.
  • physiologically acceptable means that the peptide hydrolyzate according to the invention, or a composition containing it, is suitable for coming into contact with the skin or a mucosa without causing toxicity or intolerance reactions.
  • the biologically active peptide corresponds to the sequence SEQ ID No. 5.
  • the active ingredient according to the invention can be obtained by extraction of proteins of vegetable origin or yeast, followed by controlled hydrolysis which releases compounds of peptide nature, among which are the bioactive peptides.
  • peptide hydrolysates and in particular of low molecular weight peptide hydrolysates, has many advantages in cosmetics.
  • hydrolysis and purification make it possible to obtain more stable mixtures that are more easily standardized and that do not provoke allergic reactions in dermato-cosmetics. .
  • Said active ingredient comes from the hydrolysis of plant proteins chosen from spelled, potato, corn, pea, or yeast proteins of the Saccharomyces species.
  • plant proteins chosen from spelled, potato, corn, pea, or yeast proteins of the Saccharomyces species.
  • the plants used are not subjected to prior fermentation.
  • the invention can be carried out using seeds of einkorn or small spelled ( Triticum monococcum ), which is a very ancient diploid wheat containing a particularly high protein content (Vallega 1992).
  • the invention can also be carried out using potato tubers of the genus Solanum and more particularly of the species Solanum tuberosum.
  • the tuber does not belong to the root of the plant, but to its buried stem, from which branchlets are slighter, called rhizomes, at the extremity of which the tubercles are formed.
  • the invention can also be carried out using the seeds of one of the numerous plants of the genus Zea and preferably the species Zea mays L.
  • the plant material used will be the grain and preferentially the grain freed from its envelope by a dehulling step.
  • the invention can also be carried out using one of the many plants of the pea family (Fabaceae).
  • the plants of the pea species Pisum sativum L. are used.
  • pea also refers to the seed, itself rich in proteins (25%).
  • the plant material used will be the grain and preferentially the grain removed from its envelope by a dehulling step.
  • the invention can also be carried out using yeasts of the genus Saccharomyces; and preferentially of the species Saccharomyces cerevisiae.
  • the seeds, or a specific part of the plant are crushed using a plant grinder.
  • the powder thus obtained may subsequently be "delipidated” with the aid of a conventional organic solvent (for example an alcohol, hexane or acetone).
  • a conventional organic solvent for example an alcohol, hexane or acetone.
  • yeasts in a first stage, these are conventionally cultured in a medium adapted to their development, preferably in the presence of of lactose. They are harvested by centrifugation and then suspended in a buffer solution, preferably a phosphate buffer. In a second step, these cells are exploded using a French press or using a ball mill, the majority of the insoluble membrane components being removed by centrifugation or by filtration.
  • the proteins are then extracted by the conventional method (Osborne, 1924) modified; the plant mash or the yeast lysate is suspended in an alkaline solution containing an insoluble polyvinylpolypyrrolidone adsorbent material (PVPP) (0.01-20%); in fact, it has been observed that the hydrolysis and subsequent purification operations are facilitated by this means. In particular, the concentration of phenolic-type substances, interacting with proteins, is significantly reduced.
  • PVPP polyvinylpolypyrrolidone adsorbent material
  • the soluble fraction, containing proteins, carbohydrates and possibly lipids, is collected after centrifugation and filtration steps. This crude solution is then hydrolyzed under mild conditions to generate soluble peptides.
  • Hydrolysis is defined as a chemical reaction involving the cleavage of a molecule by water, this reaction being possible in a neutral, acidic or basic medium.
  • the hydrolysis is carried out chemically and / or advantageously by proteolytic enzymes.
  • endoproteases of plant origin papain, bromelain, ficin
  • microorganisms Aspergillus, Rhizopus, Bacillus, etc.
  • the hydrolysis conditions are chosen to promote the enrichment of bioactive peptide.
  • the filtrate (solution) obtained is a first form of the active ingredient according to the invention.
  • the hydrolyzate obtained at this stage can be further purified in order to select the fractions of low molecular weight, preferably less than 6 kDa, and the peptides generated according to their nature. Fractionation can advantageously be carried out by successive ultrafiltration steps through decreasing porosity filters, by retaining the filtrates at each stage and / or by a chromatographic type method, in order to specifically enrich the hydrolyzate with bioactive peptide. .
  • a dilution phase is carried out in water or in any mixture containing water and then sterilized by ultrafiltration in order to obtain a peptide hydrolyzate characterized by a protein content of 0.5 to 5.5 g / l. .
  • This peptide hydrolyzate corresponds to the most purified form of the active principle according to the invention.
  • the peptide hydrolyzate obtained according to the invention is analyzed qualitatively and quantitatively in high pressure liquid chromatography (HPLC), making it possible to analyze proteins having molecular weights of 0.2 to 25 kDa (according to a suitable solvent gradient).
  • HPLC high pressure liquid chromatography
  • the different peptide fractions that could be isolated are then analyzed for their biological effectiveness. These various fractions are then analyzed by mass spectrometry to specifically identify the amino acid content of the peptides of each peak. Sequencing analysis was also performed to determine the peptide sequence of the bioactive peptide.
  • the hydrolyzate obtained is composed of peptides with a molecular weight of less than 6 kDa and enriched in a bioactive peptide of 4 to 6 amino acids comprising at least one glycine residue, a leucine residue and a glutamic acid residue.
  • the second object of the present invention is a composition
  • a composition comprising, in a physiologically acceptable medium, as an active ingredient capable of reinforcing the barrier function of the epidermis, the peptide hydrolyzate enriched in bioactive peptide according to the invention at a concentration of between 0.0001% and 20% approximately, and preferably at a concentration between 0.05% and 5% relative to the total weight of the final composition.
  • the active principle according to the invention is solubilized in one or more physiologically acceptable solvents, conventionally used by those skilled in the art, such as water, glycerol, ethanol and propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols, cyclic polyols, petroleum jelly, a vegetable oil or any mixture of these solvents.
  • physiologically acceptable solvents such as water, glycerol, ethanol and propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols, cyclic polyols, petroleum jelly, a vegetable oil or any mixture of these solvents.
  • the active principle according to the invention is previously solubilized in a cosmetic or pharmaceutical vector such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in, or attached to, any physiologically acceptable vector.
  • a cosmetic or pharmaceutical vector such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in, or attached to, any physiologically acceptable vector.
  • compositions that can be used according to the invention may in particular consist of a composition for hair care, and in particular a shampoo, a conditioner, a treatment lotion, a cream or a styling gel, a restructuring lotion for the hair, a mask, etc. .
  • the composition may also be in the form of a dye or mascara to be applied by brush or comb, in particular on eyelashes, eyebrows or hair.
  • compositions that can be used according to the invention can be applied by any appropriate route, in particular oral, parenteral or topical, and the formulation of the compositions will be adapted by those skilled in the art, in particular for cosmetic or dermatological compositions.
  • the compositions according to the invention are intended for topical administration. These compositions must therefore contain a physiologically acceptable medium, that is to say compatible with the skin and superficial body growths, and cover all cosmetic or dermatological forms.
  • active ingredient according to the invention can be used alone or in combination with other active ingredients.
  • compositions that can be used according to the invention also contain various protective or anti-aging active ingredients intended to promote and complete the action of said active ingredient.
  • protective or anti-aging active ingredients intended to promote and complete the action of said active ingredient.
  • Mention may be made of, without limitation, the following ingredients: cicatrizing, anti-aging, anti-wrinkle, soothing, anti-radical, anti-UV agents, agents stimulating the synthesis of dermal macromolecules or energy metabolism, moisturizing agents , antibacterials, antifungals, anti-inflammatories, anesthetics, agents modulating differentiation, pigmentation or skin depigmentation, agents stimulating the growth of nails or hair.
  • an agent having an anti-wrinkle activity such as an anti-radical or antioxidant agent, or an agent stimulating the synthesis of dermal macromolecules, an energy metabolism stimulating agent, a metalloproteinase inhibitor, will be used.
  • active ingredients having an anti-radical or antioxidant action selected from vitamin C, vitamin E, coenzyme Q10 and polyphenolic extracts of plants, retinoids.
  • composition according to the invention can also associate with the active principle according to the invention, other active ingredients stimulating the synthesis of dermal macromolecules (laminin, fibronectin, collagen), for example the collagen peptide marketed under the name “Collaxyl ® " by Vincience.
  • active ingredients stimulating the synthesis of dermal macromolecules (laminin, fibronectin, collagen), for example the collagen peptide marketed under the name “Collaxyl ® " by Vincience.
  • composition according to the invention may also be associated with the active ingredient according to the invention, other active agents stimulating energy metabolism, as the active ingredient sold under the name "GP4G ®" by Vincience.
  • the invention is directed to mammals in general, and more particularly to humans.
  • compositions may especially be in the form of an aqueous solution, hydroalcoholic or oily; an oil-in-water, water-in-oil emulsion or multiple emulsions; they may also be in the form of creams, suspensions or powders, suitable for application to the skin, mucous membranes, lips and / or integuments.
  • These compositions may be more or less fluid and have the appearance of a cream, lotion, milk, serum, ointment, gel, paste or paste. a foam. They can also be in solid form, as a stick or be applied to the skin in aerosol form. They can be used as a care product and / or as a make-up product for the skin.
  • compositions additionally comprise any additive commonly used in the intended field of application and the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, other cosmetic active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
  • additives such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, other cosmetic active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
  • these adjuvants and their proportions are chosen so as not to adversely affect the desirable properties of the composition according to the invention.
  • These adjuvants may, for example, correspond to a concentration ranging from 0.01 to 20% of the total weight of the composition.
  • the fatty phase may represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition.
  • the emulsifiers and co-emulsifiers used in the composition will be chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight, relative to the total weight of the composition.
  • the third object of the invention is a pharmaceutical composition comprising an effective amount of peptide hydrolyzate according to the invention, as a medicament.
  • the pharmaceutical composition may be intended to prevent or treat pathologies characterized by an alteration of the barrier function, such as hypersensitive, irritated or reactive skin and atopic eczema.
  • compositions will be suitable for oral administration for pharmaceutical use.
  • the compositions may in particular be in the form of tablets, capsules, capsules, chewable pastes, powders to be consumed as such or to mix extemporaneously with a liquid, syrup, gels, and any other form known to those skilled in the art.
  • These compositions additionally comprise any additive commonly used in the intended field of application as well as adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, preservatives, other pharmaceutical active ingredients. , essential oils, vitamins, essential fatty acids, etc.
  • the fourth subject of the invention is the cosmetic use, in a composition, of an effective amount of peptide hydrolyzate according to the invention, as activating active ingredient of human HMG-CoA reductase, in order to reinforce the barrier function of epidermis and stimulate epidermal differentiation.
  • the effective amount of active ingredient is the amount necessary to achieve the desired result, namely, activate HMG-CoA reductase, in order to improve the barrier function of the epidermis and to stimulate epidermal differentiation.
  • the term "reinforcing the skin barrier function and stimulating epidermal differentiation” means improving the protection capacity of the stratum corneum and increasing the expression of biological markers of differentiations, such as keratins.
  • said active ingredient can be used in a cosmetic composition intended to reinforce the cutaneous barrier function and to stimulate epidermal differentiation.
  • the peptide hydrolyzate can advantageously be used, as an active ingredient, in a cosmetic composition intended to fight in a preventive and / or curative manner against the signs of skin aging, and more particularly of photo-induced skin aging.
  • photoaging By cutaneous signs of aging or photo-aging means any changes in the external appearance of the skin and skin appendages due to aging, such as, for example, the superficial roughness of the stratum corneum, wrinkles and fine lines, but also any internal modification of the skin. skin that does not systematically result in a modified external appearance such as, for example, thinning of the epidermis or any other internal degradation of the skin resulting from exposure to ultraviolet (UV) radiation.
  • UV ultraviolet
  • the peptide hydrolyzate may advantageously be used as an active ingredient in a cosmetic composition intended to protect the skin against all types of external aggressions.
  • external aggression refers to the aggression that the environment can produce.
  • aggressions such as pollution, UV, or irritating products such as surfactants, preservatives or perfumes
  • mechanical aggression such as abrasions, shaving or blighting. 'hair removal.
  • Pollution is understood to mean both “external” pollution due for example to diesel particles, ozone or heavy metals, and “internal” pollution, which may be due in particular to solvent emissions from paints, glues, or wallpaper (such as toluene, styrene, xylene or benzaldehyde), or even cigarette smoke.
  • the dryness of the atmosphere is also an important cause of skin aggression.
  • the subject of the invention is the cosmetic use of the hydrolyzate according to the invention in a composition intended to prevent or treat the damage caused to the skin by external aggressions of the skin, chosen from mechanical treatments such as shaving or waxing, excessive leaching by detergents, extreme weather conditions or sudden changes in temperature and humidity.
  • the subject of the invention is a cosmetic treatment method intended to prevent and / or fight against the cutaneous signs of aging and / or photo-aging. according to which a composition comprising an effective amount of peptide hydrolyzate according to the invention is applied to the zones to be treated.
  • the grains of spelled ( Triticum monococcum ) are dissolved in 10 volumes of water in the presence of 2% of POLYCLAR® 10 (polyvinylpyrrolidone - PVPP - insoluble). The mixture is adjusted to a pH of between 6 and 8 with a 1M aqueous sodium hydroxide solution.
  • an amylase hasidase®
  • a protease papain 26%
  • the hydrolysis is obtained after 2 hours of stirring at 50 ° C.
  • the enzyme is then inactivated by heating the solution at 80 ° C for 2 hours. After centrifugation, the supernatant aqueous solution corresponding to a crude hydrolyzate of spelled is recovered.
  • Hydrolysis conditions were chosen so as to allow enrichment of bioactive peptide of 4 to 6 amino acids containing residues Gly, Leu and glutamic acid.
  • the purification process of the crude hydrolyzate starts with successive filtrations using Seitz-Orion plate filters of decreasing porosity (up to 0.2 ⁇ m) in order to obtain a brilliant and clear solution, qualified as hydrolyzate 1.
  • the spelled hydrolyzate 1 is characterized by a light yellow color and by a solids content of 20 to 25 g / kg, a protein content of 10 to 12 g / l and a sugar content of 5. at 8 g / l.
  • the protein nature of the hydrolyzate 1 is demonstrated after analysis by NuPAGE® Bis-Tris Pre-cast polyacrylamide gel electrophoresis (Invitrogen).
  • the spelled protein hydrolyzate is heated at 70 ° C for 10 minutes under denaturing reducing conditions in NuPAGE® LDS sample preparation buffer.
  • a solution of NuPAGE® Antioxidant is added to the inner vessel (cathode) to prevent the reduced proteins from re-oxidizing during electrophoresis.
  • Protein migration is performed in NuPAGE® MES Migration Buffer with the SeeBlue Plus2 standard as a molecular weight marker. Protein staining is performed using Coomassie® Blue R-250. Under these conditions, a 24 kDa band corresponding to the enzyme is observed, followed by proteins less than 6 kDa.
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • PICT phenylisothiocyanate
  • amino acid composition of the hydrolyzate is given in the following table (in%): Amino acids % alanine 3.1 Aspartic acid 4.7 arginine 3.1 Glutamic acid 32.8 wistaria 3.1 histidine ⁇ 3.0 isoleucine ⁇ 5.5 leucine 6.2 lysine ⁇ 2.2 phenylalanine 4.5 proline 10.9 drummed 4.7 threonine 3.1 tyrosine ⁇ 3.6 valine 4.7 tryptophan ⁇ 1.5
  • the potato tubers ( Solanum tuberosum ) are dissolved in 10 volumes of water in the presence of 2% of POLYCLAR® 10 (polyvinylpyrrolidone - PVPP - insoluble). The mixture is adjusted to a pH of between 6 and 8 with a 1M aqueous sodium hydroxide solution. Precipitation in an acid medium is then carried out. The pellet is put back into solution and after adjusting the pH, 2% papain is added to the medium reaction. The hydrolysis is obtained after stirring for 2 hours at 55 ° C. The enzyme is then inactivated by heating the solution at 80 ° C for 2 hours. After centrifugation, the supernatant aqueous solution corresponding to a crude potato hydrolyzate is recovered. The hydrolysis conditions were chosen so as to allow enrichment of bioactive peptide of 4 to 6 amino acids containing residues Gly, Leu and Glu.
  • the purification process of the crude hydrolyzate begins with successive filtrations using Seitz-Orion plate filters of decreasing porosity (up to 0.2 ⁇ m) in order to obtain a bright and clear yellow solution, qualified hydrolyzate 1.
  • the potato hydrolyzate 1 is characterized by a solids content of 40 to 60 g / kg, a protein content of 20 to 25 g / l and a sugar content of 1 to 3 g / l. .
  • the protein nature of the hydrolyzate 1 is demonstrated after analysis by electrophoresis on polyacrylamide gel NUAGE® Bis-Tris Pre-cast (Invitrogen).
  • the potato protein hydrolyzate is heated at 70 ° C for 10 minutes under denaturing reducing conditions in NuPAGE® LDS sample preparation buffer.
  • a solution of NuPAGE® Antioxidant is added to the inner vessel (cathode) to prevent the reduced proteins from re-oxidizing during electrophoresis.
  • Protein migration is performed in NuPAGE® MES Migration Buffer with the SeeBlue Plus2 standard as a molecular weight marker. Protein staining is performed using Coomassie® Blue R-250. Under these conditions, it is observed that the proteins obtained have a molecular weight of less than 6 kDa.
  • the hydrolyzate 1 is then purified in order to retain only peptides with a molecular weight of less than 5 kDa, using tangential flow filtration.
  • the hydrolyzate 1 is pumped under pressure through a Pellicon® support equipped with Pellicon® 2 Biomax 5 kDa cassette.
  • a brilliant and limpid peptide hydrolyzate is obtained.
  • a dilution phase is then carried out in order to obtain a peptide hydrolyzate characterized by a protein content of 3.5 to 5.5 g / l.
  • This peptide hydrolyzate corresponds to the active principle according to the invention.
  • This peptide hydrolyzate is then analyzed by high pressure liquid chromatography (HPLC) using an HP1100 device controlled by the ChemStation software.
  • HPLC high pressure liquid chromatography
  • the column used during the elution of the hydrolyzate is a Nucleosil® 300-5 C4 MPN (125 x 4 min), allowing the chromatography of proteins having molecular weights of 0.2 to 25. kDa (according to conditions identical to example 1). In these chromatographic conditions, several peptide fractions could be isolated.
  • FIG. figure 2 An example of a chromatogram obtained by HPLC (high-pressure liquid chromatography), with the peak corresponding to the bioactive peptide, is given in FIG. figure 2 .
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • PICT phenylisothiocyanate
  • amino acid composition of the hydrolyzate is given in the following table (in%): Amino acids % alanine 7.8 Aspartic acid 20.1 Arqinine 7.3 Glutamic acid 17.4 wistaria 7.3 histidine 3.2 isoleucine 9.1 leucine 15.1 lysine 11.4 phenylalanine 8.7 proline 7.7 serine 8.7 threonine 9.1 tyrosine 8.2 valine 10.5 tryptophan 1.4
  • Example 3 Preparation of a peptide hydrolyzate from corn cakes (Zea mays L.)
  • the corn meal ( Zea mays L. ) is dissolved in 10 volumes of water in the presence of 2% of POLYCLAR® 10 (polyvinylpyrrolidone - PVPP - insoluble). The mixture is adjusted to a pH of between 6 and 8 with a 1M aqueous sodium hydroxide solution.
  • POLYCLAR® 10 polyvinylpyrrolidone - PVPP - insoluble
  • the process of purification of the crude hydrolyzate begins with successive filtrations using Seitz-Orion plate filters of decreasing porosity (up to 0.2 ⁇ m) in order to obtain a yellow, brilliant and clear solution, qualified of hydrolyzate 1.
  • the maize hydrolyzate 1 is characterized by a solids content of 20 to 30 g / kg, a protein content of 20 to 25 g / l and a sugar content of 2 to 5 g / l.
  • the protein nature of the hydrolyzate 1 is demonstrated after analysis by NuPAGE® Bis-Tris Pre-cast polyacrylamide gel electrophoresis (Invitrogen).
  • the corn protein hydrolyzate is heated at 70 ° C for 10 minutes under denaturing reducing conditions in NuPAGE® LDS sample preparation buffer.
  • a solution of NuPAGE® Antioxidant is added to the inner vessel (cathode) to prevent the reduced proteins from re-oxidizing during electrophoresis.
  • Protein migration is performed in NuPAGE® MES Migration Buffer with the SeeBlue Plus2 standard as a molecular weight marker. Protein staining is performed using Coomassie® Blue R-250. Under these conditions, proteins with a molecular weight of less than 6 kDa are observed.
  • the hydrolyzate 1 is then purified by removing the high molecular weight proteins by ultrafiltration using the Pellicon® 2 Biomax 5 kDa cassette in order to keep only the peptidic compounds of less than 5 kDa,
  • a dilution phase is carried out in order to obtain a peptide hydrolyzate characterized by a protein content of between 3.5 and 5.5 g / l.
  • This peptide hydrolyzate corresponds to the active principle according to the invention.
  • This peptide hydrolyzate is then analyzed by high pressure liquid chromatography (HPLC) using an HP1100 device controlled by the ChemStation software.
  • HPLC high pressure liquid chromatography
  • the column used during the elution of the hydrolyzate is a Nucleosil® 300-5 C4 MPN (125 x 4 min), allowing the chromatography of proteins having molecular weights from 0.2 to 25 kDa (according to a suitable solvent gradient, identical in example 1). In these chromatographic conditions, several peptide fractions could be isolated.
  • FIG. figure 3 An example of a chromatogram obtained by HPLC (high-pressure liquid chromatography), with the peak corresponding to the bioactive peptide, is given in FIG. figure 3
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • An example of the amino acid composition of the hydrolyzate is given in the following table (%): Amino acids % alanine 9.4 Aspartic acid 7.2 arginine 3.6 Glutamic acid 23.7 wistaria 3.6 histidine 2.2 isoleucine 4.5 leucine 16.1 lysine 2.2 phenylalanine 6.7 proline 10.3 serine 6.3 threonine 4.0 tyrosine 5.8 valine 5.4 tryptophan ⁇ 0.5
  • the peptide hydrolyzate is obtained from an extract of plants of the species Pisum sativum L.
  • the extract can be prepared from plants of at least one of the many varieties and species belonging to the genus Pisum.
  • the pea flour thus obtained is dissolved in 10 volumes of water in the presence of 2% of POLYCLAR® 10 (polyvinylpyrrolidone - PVPP - insoluble).
  • POLYCLAR® 10 polyvinylpyrrolidone - PVPP - insoluble.
  • the mixture is adjusted to a pH of between 6 and 7 with a 1 M aqueous sodium hydroxide solution.
  • the hydrolysis is obtained after 2 hours of stirring at 50 ° C.
  • the enzyme is inactivated by heating the solution at 80 ° C for 2 hours.
  • the reaction mixture thus obtained corresponds to the pea extract.
  • the hydrolysis conditions were chosen so as to allow an enrichment in bioactive peptide of 4 to 6 amino acids containing the residues Gly, Leu and glutamic acid.
  • the purification process begins with successive filtrations using decreasing porosity Seitz-Orion plate filters (up to 0.2 ⁇ m) to obtain a brilliant and clear solution.
  • the pea hydrolyzate is characterized by a dryness of 70-80 g / kg, a protein content of 55-65 g / l, a sugar content of 2-5 g / l and a polyphenol content. 1-3 g / l.
  • This solution is then purified by removing the molecular weight proteins greater than 5 kDa using tangential flow filtration.
  • the pea hydrolyzate is pumped under pressure through a Pellicon® support equipped with a Pellicon® 2 Biomax 30 kDa cassette. This first filtrate is recovered and then filtered through another Pellicon® 2 Biomax 5 kDa cassette. At the end of purification, a yellow-beige pea peptide hydrolyzate is obtained which is brilliant and clear. It is characterized by a dryness of 50 to 55 g / kg, a protein content of 50 to 52 g / l.
  • This solution is then analyzed in high pressure liquid chromatography using an HP1100 device controlled by the ChemStation software.
  • the column used during the elution of the pea extract is a Nucleosil® 300-5 C4 MPN (125 x 4 min). This This column makes it possible to chromatograph proteins having molecular weights of 0.2 to 25 kDa (according to a suitable solvent gradient, identical to Example 1). In these chromatographic conditions, several peptide fractions could be isolated.
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • PICT phenylisothiocyanate
  • the active principle is obtained from plants of the species Glycine max L.
  • the extract can be prepared from plants of at least one of the many varieties and species belonging to the genus Glycine.
  • the cakes are the solid residues obtained after extraction of the oil from the soya beans. They represent 50 to 75% of the seed mass.
  • a first step 1 kg of soybean meal is milled in a cereal mill.
  • the flour obtained is delipidated by the action of an organic solvent, hexane.
  • the powder obtained is suspended in an aqueous alkaline solution (1/10 dilution) pH 10, containing 1% of polyvinylpolypyrrolidone (Polyclar V ISP). This mixture is stirred for a time long enough to allow the solubilization of the soluble fractions.
  • the extraction temperature is variable (between 4 and 80 ° C); preferably the operation will be performed cold. After this extraction phase, the medium is clarified by centrifugation and then filtered through a plate filter.
  • This filtrate which contains the soluble fractions of soybeans, is then precipitated by varying the ionic strength in a neutral or acidic medium to remove soluble carbohydrate components, lipids, and nucleic acids.
  • the medium is brought at pH 3.5.
  • the supernatant is removed and the precipitate is then washed with a solvent such as, for example, ethanol or methanol, and the solvent is evaporated by drying in vacuo.
  • the protein-rich precipitate is dissolved in water or another solvent.
  • the crude protein extract is then subjected to a series of gentle and selective hydrolyses consisting of chemical and enzymatic hydrolyses in the presence of 0.5% PVPP (Polyclar V) and cysteine endopeptidases (papain, ficin). After reaction, the hydrolyzate is filtered on a plate and then on a sterilizing cartridge (0.2 ⁇ m).
  • PVPP Polyclar V
  • cysteine endopeptidases papain, ficin
  • the hydrolysis conditions were chosen so as to allow an enrichment in bioactive peptide of 4 to 6 amino acids containing the residues Gly, Leu and glutamic acid.
  • the solution is then ultrafiltered on a Millipore Helicon filtration cartridge (1 kDa cutoff).
  • the high molecular weights contained in the retentate are removed, the filtrate is preserved.
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • PICT phenylisothiocyanate
  • One variant of the protocol consists in carrying out a purification of the active principle, obtained according to the preceding protocol, by ion exchange chromatography, on a TSK gel column (TosoHaas) with a pH 7 phosphate buffer, in order to enrich the hydrolyzate Peptide peptide bioactive.
  • Example 6 Preparation of a peptide hydrolyzate from yeasts Saccharomyces cerevisiae
  • the peptide hydrolyzate may be obtained from a yeast extract of the Saccharomyces cerevisiae species .
  • the yeasts are cultured in a medium adapted to their development, preferably in the presence of lactose, and then centrifuged to recover a biomass.
  • the Saccharomyces biomass is dissolved in 10 volumes of water in the presence of 2% of POLYCLAR® 10 (polyvinylpyrrolidone - PVPP - insoluble) and 0.2% of activated carbon.
  • the mixture is adjusted to a pH of between 6 and 7.5 with a 1M aqueous sodium hydroxide solution.
  • the hydrolysis is obtained after stirring for 2 hours at 55 ° C.
  • the enzyme is inactivated by heating the solution at 80 ° C for 2 hours. After centrifugation, the reaction mixture corresponding to the Saccharomyces extract is then obtained.
  • the hydrolysis conditions were chosen so as to allow an enrichment in bioactive peptide of 4 to 6 amino acids containing the residues Gly, Leu and glutamic acid.
  • the purification process starts with successive filtrations using Seitz-Orion plate filters of decreasing porosity (up to 0.2 ⁇ m) in order to obtain a solution brilliant and limpid.
  • the Saccharomyces extract is characterized by a dryness of 25 to 35 g / kg, a protein content of 10 to 15 g / l and a sugar content of 5-10 g / l.
  • This solution is then purified by removing proteins of molecular weight greater than 5 kDa using tangential flow filtration.
  • Saccharomyces peptide hydrolyzate is pumped under pressure through a Pellicon® support, equipped with a 50 kDa Pellicon® 2 Biomax cassette. This first filtrate is recovered and then filtered through a second Pellicon® 2 Biomax 10 kDa cassette. A second filtrate is then recovered which is still eluted through a last Pellicon® 2 Biomax 5 kDa cassette.
  • a vegetable extract of beige, brilliant and limpid saccharomyces is obtained. It is characterized by a dryness of 35 to 45 g / kg, a protein content of 30 to 40 g / l.
  • This solution is then analyzed in high pressure liquid chromatography using an HP1100 device controlled by the ChemStation software.
  • the column used during the elution of the saccharomyces hydrolyzate is a Nucleosil® 300-5 C4 MPN (125 x 4 min). This column makes it possible to chromatograph proteins having molecular weights of 0.2 to 25 kDa (according to a suitable solvent gradient, identical to Example 1). In these chromatographic conditions, several peptide fractions have been isolated.
  • the determination of the amino acid composition of the active ingredient according to the invention has also been carried out. This is carried out after acid hydrolysis and identification by high pressure liquid chromatography using pre-derivation with PICT (phenylisothiocyanate).
  • PICT phenylisothiocyanate
  • the aim of this study is to study ultrastructurally, by transmission electron microscopy, keratinocytes treated with the hydrolyzate according to Example 1 at 1%.
  • the cells are mixed with 2% agar and then post-fixed with osmium tetroxide for 1 hour.
  • the specimens are then dehydrated by successive passages in a series of alcohol (from 50 to 100%).
  • the cells are then coated in a resin.
  • the polymerization is carried out for about 12 hours at 60 ° C.
  • Semi-fine sections of 0.5 ⁇ m are made with ultra-microtome. The sections are deposited on a heat-bonded slide and then stained with toluidine blue. The slides are then dehydrated again and mounted in a suitable medium.
  • the block is resized to the desired size and ultrafine sections are then made, only sections that have a "gray-silver" color and an adequate size are mounted on the electron microscopy grid doubly labeled with uranyl acetate and lead citrate, and examined under a transmission microscope at 60 or 80 KV.
  • the hydrolyzate according to Example 1 to 1% is capable of inducing an increase in lipid synthesis in normal human keratinocytes.
  • the aim of this study is to study ultrastructurally the caveolae in human dermal fibroblasts.
  • Example 9 Study of the Differentiation of Human Keratinocytes Treated with the Hydrolyzate According to Example 2
  • the purpose of this study is to determine the influence of the hydrolyzate according to the example on epidermal differentiation, and more particularly on the expression of all cytokeratins (or pankeratins), which are markers of keratinocyte differentiation. .
  • the purpose of this study is to determine the protective effect of the hydrolyzate according to Example 2 vis-à-vis normal human keratinocytes subjected to stress by UVB radiation. For this, cell viability tests were performed by the MTT technique.
  • This compound is absorbed by living cells and then metabolized by the mitochondrial enzymes into a blue violet compound, formazan, which will be assayed spectrophotometrically at 540 nm.
  • the optical density (OD) is then directly proportional to the mitochondrial enzymatic activity as well as to the number of living cells.
  • Example 11 Study of HMG-CoA Reductase Exurse in Skin Biopsies in the Presence of the Hydrolyzate According to Example 1
  • the purpose of this study is to determine the influence of the hydrolyzate according to Example 1 at 0.5% on the expression of HMG-CoA reductase.
  • the purpose of this study is to determine the influence of the hydrolyzate according to Example 2 on the expression of HMG-CoA reductase in normal human keratinocytes.
  • phase A and phase B are heated separately between 70 ° C and 75 ° C.
  • Phase B is emulsified in phase A with stirring.
  • Phase C is added at 45 ° C, increasing stirring.
  • Phase D is then added when the temperature is below 40 ° C. Cooling is continued up to 25 ° C with vigorous stirring.
  • phase A Prepare and melt phase A at 65-70 ° C. Heat phase C at 65-70 ° C. Phase B is added to the Adjust phase before emulsifying A in B. At about 45 ° C, the carbomer is neutralized by the addition of phase D. Phase E is then added with gentle stirring and cooling is continued. at 25 ° C. Phase F is then added if desired.
  • phase A Prepare phase A and heat to 75 ° C with stirring.
  • phase B by dispersing the carbopol, then the xanthan gum with stirring. Let rest. Heat to 75 ° C.
  • phase C At temperature, emulsify A in B with rotor-stator stirring. Neutralize with phase C with rapid stirring. After cooling to 40 ° C., add phase D and then phase E. Cooling is continued with gentle stirring and phase F added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (10)

  1. Aktivierendes Peptidhydrolysat von HMG-CoA-Reduktase, dadurch gekennzeichnet, dass es aus der Hydrolyse von Pflanzen hervorgeht, die aus Dinkel (Triticum monococum), Kartoffel (Solanum tuberosum), Mais (Zea mayz L.), Erbse (Pisum sativum) oder Hefen der Gattung Saccharomyces und insbesondere der Spezies Saccharomyces cerevisiae ausgewählt sind, sich aus Peptiden mit einem Molekulargewicht von weniger als 6 kDa zusammensetzt und mit bioaktivem Peptid angereichert ist, das die Barrierefunktion der Epidermis verstärken kann, wobei das besagte bioaktive Peptid 4 bis 6 Aminosäuren enthält, darunter mindestens einen Glycinrest, einen Leucinrest und einen Glutaminsäurerest, und eine Sequenz der folgenden allgemeinen Formel (I) aufweist:
    X1-[Gly, Glu, Leu]-X2-X3,
    in der
    X1 Alanin, Valin, Isoleucin oder keine Aminosäure ist,
    X2 Serin oder Threonin ist,
    X3 Leucin, Isoleucin oder keine Aminosäure ist,
    und die aus den folgenden Sequenzen ausgewählt ist:
    (SEQ ID Nr. 1) Ala-Glu-Gly-Leu-Ser-Ile
    (SEQ ID Nr. 2) Leu-Gly-Glu-Ser-Leu
    (SEQ ID Nr. 3) Val-Gly-Glu-Leu-Thr
    (SEQ ID Nr. 4) Ile-Gly-Glu-Leu-Ser
    (SEQ ID Nr. 5) Ala-Gly-Glu-Leu-Ser
    (SEQ ID Nr. 6) Gly-Glu-Leu-Thr-Ile
    (SEQ ID Nr. 7) Gly-Glu-Leu-Ser.
  2. Peptidhydrolysat nach dem vorhergehenden Anspruch, dadurch gekennzeichnet, dass es zwischen 0,5 und 5,5 g/l natürlicher Peptidverbindungen enthält.
  3. Kosmetische Zusammensetzung, die in einem physiologisch akzeptablen Medium als Wirkstoff, der die Barrierefunktion der Epidermis verstärken kann, das in einem der vorhergehenden Ansprüche definierte Peptidhydrolysat in einer Menge umfasst, die 0,0001 % bis 20 % des Gesamtgewichts der Zusammensetzung ausmacht, und vorzugsweise in einer Menge umfasst, die 0,05 % bis 5 % des Gesamtgewichts der Zusammensetzung ausmacht.
  4. Zusammensetzung nach Anspruch 3, dadurch gekennzeichnet, dass sie in einer Form dargereicht wird, die für eine topische Anwendung geeignet ist.
  5. Zusammensetzung nach einem der Ansprüche 3 oder 4, dadurch gekennzeichnet, dass sie außerdem mindestens einen anderen Wirkstoff umfasst, der die Wirkung des besagten Peptidhydrolysats begünstig und aus Vitamin C, Vitamin E, Coenzym Q10, polyphenolischen Pflanzenextrakten, Retinoiden, dem Peptid mit der Sequenz Gly-Pro-Gln-Gly-Pro-Gln (COLLAXYL®) und dem Artemia-Extrakt (GP4G®) ausgewählt ist.
  6. Pharmazeutische Zusammensetzung, die in einem physiologisch akzeptablen Medium das in einem der Ansprüche 1 oder 2 definierte Peptidhydrolysat umfasst, als Arzneimittel.
  7. Kosmetische Verwendung einer wirksamen Menge eines Peptidhydrolysats nach einem der Ansprüche 1 oder 2 zum Verstärken der Barrierefunktion der Epidermis und zum Stimulieren der epidermalen Differenzierung.
  8. Verwendung nach Anspruch 7 zum Verhindern und Bekämpfen von Zeichen der Alterung und der Lichtalterung der Haut.
  9. Verwendung nach Anspruch 7 zum Schützen der Haut vor äußeren Einflüssen.
  10. Verfahren zur kosmetischen Behandlung, die dazu vorgesehen ist, Manifestationen der Alterung und/oder der Lichtalterung der Haut zu bekämpfen oder zu behandeln, dadurch gekennzeichnet, dass eine Zusammensetzung, die eine wirksame Menge des wie in einem der Ansprüche 1 oder 2 definierten Peptidhydrolysats umfasst, topisch auf die zu behandelnde Haut oder die zu behandelnden Hautanhangsgebilde aufgebracht wird.
EP10718238.8A 2009-04-15 2010-04-15 Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung Active EP2419438B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901822A FR2944526B1 (fr) 2009-04-15 2009-04-15 Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barriere
PCT/FR2010/000311 WO2010119191A1 (fr) 2009-04-15 2010-04-15 Composition cosmétique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barrière

Publications (2)

Publication Number Publication Date
EP2419438A1 EP2419438A1 (de) 2012-02-22
EP2419438B1 true EP2419438B1 (de) 2015-07-15

Family

ID=40973217

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10718238.8A Active EP2419438B1 (de) 2009-04-15 2010-04-15 Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung

Country Status (7)

Country Link
US (1) US8674072B2 (de)
EP (1) EP2419438B1 (de)
JP (1) JP2012524049A (de)
CN (1) CN102459310B (de)
ES (1) ES2549392T3 (de)
FR (1) FR2944526B1 (de)
WO (1) WO2010119191A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962038B1 (fr) * 2010-07-01 2013-01-18 Isp Investments Inc Utilisation d'un extrait peptidique de pois en tant qu'agent actif antioxydant dans une composition cosmetique
CN102579297B (zh) * 2012-03-16 2013-05-01 深圳市金因生物技术有限公司 提高皮肤耐受力的化妆品及其制备方法
FR2987998B1 (fr) * 2012-03-19 2014-04-25 Isp Investments Inc Composition cosmetique comprenant un systeme activateur de la proteine trf2 a action synergique constitue d'une association d'un extrait peptidique de soja et de levure et ses utilisations
FR2998178B1 (fr) * 2012-11-19 2015-11-13 Isp Investments Inc Utilisation d'un peptide derive de hmg-coa reductase pour apaiser la muqueuse buccale
CN103315934B (zh) * 2013-06-21 2014-07-09 深圳市金因生物技术有限公司 促进皮肤水通道蛋白开启的组合物及其制备方法
AU2015247418A1 (en) 2014-04-18 2016-12-08 Gregory P. Pilant Methods and compositions for topical delivery for skin care
FR3034664B1 (fr) 2015-04-09 2018-09-14 ISP Investments LLC. Extrait hydro-alcoolique de schinus molle, compositions cosmetiques le comprenant et leurs utilisations cosmetiques
FR3043695B1 (fr) 2015-11-17 2019-10-25 ISP Investments LLC. Procede d'obtention d'un extrait aqueux enrichi en petits arn a partir d'une matiere vegetal et extraits issus du procede
FR3048610B1 (fr) 2016-03-08 2020-03-27 ISP Investments LLC. Corps gras active et/ou cire activee au moyen de la fraction non hydrosoluble du suc de carica papaya
EP3509707B1 (de) 2016-09-07 2020-08-12 ISP Investments LLC Wasserauszug von prunus persica und verfahren zu seiner herstellung
FR3062568B1 (fr) 2017-02-09 2020-10-23 Isp Investments Llc Extraits de la liane marsdenia cundurango, compositions cosmetiques les comprenant et leurs utilisations cosmetiques.
CN108721155B (zh) 2017-04-14 2023-03-17 Isp投资有限公司 含有白松露提取物的化妆品制备物和其化妆方法
FR3066113B1 (fr) 2017-05-12 2020-06-05 ISP Investments LLC. Procede d’obtention d’un extrait aqueux d’anethum graveolens enrichi en petits arn
FR3077204B1 (fr) 2018-01-30 2021-09-17 Isp Investments Llc Extraits de fruit de myrciaria dubia riche en acides organiques, compositions cosmetiques le comprenant et leurs utilisations cosmetiques
FR3091993B1 (fr) 2019-01-29 2021-01-22 Isp Investments Llc Procede d’obtention d’un extrait de feuilles de patchouli et ses utilisations cosmetiques
FR3106754B1 (fr) 2020-02-04 2022-01-07 Isp Investments Llc Procede d’obtention d’un extrait aqueux de lavande, compositions comprenant un tel extrait et leurs utilisations cosmetiques
FR3110425B1 (fr) 2020-05-19 2022-09-09 Isp Investments Llc Procede d’obtention d’un extrait de bois de santal, compositions le comprenant et ses utilisations cosmetiques
CN114081852A (zh) 2020-08-25 2022-02-25 Isp投资有限公司 改善皮肤外观的组合物和方法
FR3116438B1 (fr) 2020-11-23 2022-10-14 Isp Investments Llc Procede d’obtention d’extraits aqueux de feuilles de thes, compositions comprenant de tels extraits et leurs utilisations cosmetiques
CN115252513A (zh) * 2021-04-29 2022-11-01 上海全丽生物科技有限公司 五谷发酵物的制造方法及含其的化妆品组成物
KR102614707B1 (ko) * 2021-05-28 2023-12-15 주식회사 인투바이오 아미노산 함량이 증가된 클로렐라 불가리스 추출물의 제조방법 및 이를 함유하는 화장료 조성물
FR3125425B1 (fr) 2021-07-22 2024-09-13 Isp Investments Llc Extrait de feuilles de the noir, compositions le comprenant et ses utilisations cosmetiques
FR3146596A1 (fr) 2023-03-15 2024-09-20 ISP Investments LLC. Procede d’obtention d’un extrait de bois de rose, compositions le comprenant et ses utilisations cosmetiques

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4139619A (en) 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
JP2751161B2 (ja) 1986-10-13 1998-05-18 味の素株式会社 栄養組成物
DE68917946T2 (de) 1988-01-29 1995-01-05 Peter H Proctor Haarwachstumanregung mit Nitroxyd und anderen Radikalen.
JPH07316023A (ja) 1994-05-26 1995-12-05 Shiseido Co Ltd 育毛料
JPH0848698A (ja) * 1994-08-05 1996-02-20 Seiwa Kasei:Kk 酵母タンパク誘導ペプチド組成物、その製造方法およびその用途
EP0738510A3 (de) 1995-04-20 2005-12-21 L'oreal Verwendung eines HMG-CoA-Reduktase Inhibitors als Hautalterungschutzmittel und als Anti-Aknemittel. Zusammensetzung enthaltend mindestens einen HMG-CoA-Reduktase Inhibitor und mindestens einen Wirkstoff mit abschuppenden Eigenschaften
JPH10203994A (ja) * 1997-01-27 1998-08-04 Ichimaru Pharcos Co Ltd 生理活性作用組成物
CA2243985C (en) 1997-09-11 2004-08-10 F. Hoffmann-La Roche Ag Thermostable dna polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes
FR2789312B1 (fr) 1999-02-05 2003-10-17 Seporga Sterol 3 sulfates, nouveaux principes actifs a usage cosmetique et dermatologique, et leurs applications
FR2798591B1 (fr) 1999-09-22 2001-10-26 Pharmascience Lab Utilisation d'un produit d'huile vegetale pour augmenter la synthese des lipides cutanes en cosmetique, pharmacie ou dermatologie et en tant qu'additif alimentaire
CA2954411A1 (en) * 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
US6365138B1 (en) 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
US7179590B2 (en) 2000-04-18 2007-02-20 Roche Molecular Systems, Inc High temperature reverse transcription using mutant DNA polymerases
JP3930808B2 (ja) * 2001-02-27 2007-06-13 ニューロタイド カンパニー リミテッド 抗ストレス機能、抗疲労機能、月経前期症候群及び月経痛緩和機能及び脳神経栄養因子としての機能を有する酵母由来機能性ペプチド及びその製造方法
TNSN02063A1 (en) 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
FR2827174B1 (fr) 2001-07-13 2004-08-06 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US20030100467A1 (en) 2001-09-12 2003-05-29 Wolfgang Aehle Binding phenol oxidizing enzyme-peptide complexes
DE10206353A1 (de) 2002-02-14 2003-08-28 Cognis Deutschland Gmbh Verwendung von niedermolekularen Proteinhydralysaten
GB0208331D0 (en) 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
FR2848851B1 (fr) 2002-12-20 2006-03-10 Procede d'obtention d'un principe actif presentant des capacites apaisantes, principe actif et compositions obtenues
FR2854069B1 (fr) * 2003-04-23 2006-03-10 Silab Sa Procede d'obtention d'un principe actif a partir du soja, ayant des proprietes anti-vieillissement, compositions et utilisations de ces compositions a visee cosmetique
US7431919B2 (en) 2003-08-20 2008-10-07 Avon Products, Inc Mascara composition
CA2545756A1 (en) 2003-11-07 2005-05-26 Curagen Corporation Antibodies against secretoryleukocyte protease inhibitor
US20050272097A1 (en) 2004-02-18 2005-12-08 Emanuel Calenoff Methods and compositions for detecting and treating autoimmune diseases
FR2868309B1 (fr) 2004-04-02 2006-05-26 Oreal Utilisation cosmetique d'au moins un inhibiteur d'hmg-coa-reductase comme agent destine a prevenir et/ou lutter contre les rides d'expression
FR2869228B1 (fr) 2004-04-21 2008-09-05 Vincience Sa Utilisation d'un hydrolysat de proteines de cruciferes en tant qu'agent depigmentant dans ou pour une composition cosmetique et/ou pharmaceutique
US20060263787A1 (en) 2004-05-10 2006-11-23 Evans Glen A Immunoglobulin-like variable chain binding polypeptides and methods of use
US20080268077A1 (en) 2004-10-14 2008-10-30 Symrise Gmbh & Co. Kg Process for Strengthening the Barrier Function of Undamaged Skin
FR2887772B1 (fr) 2005-07-01 2010-08-13 Soc Extraction Principes Actif Utilisation d'un extrait de levure en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau.
FR2893502A1 (fr) 2005-11-21 2007-05-25 Oreal Procede cosmetique de soin de la peau utilisant des contraintes mecaniques
WO2008015343A2 (fr) 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2904552B1 (fr) * 2006-08-03 2012-09-21 Soc Extraction Principes Actif Utilisation d'un extrait de levure en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
FR2911779B1 (fr) 2007-01-30 2009-04-24 Lvmh Rech Composition contenant un extrait d'ambre
FR2915384B1 (fr) * 2007-04-27 2010-01-15 Vincience Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2918563B1 (fr) 2007-07-12 2009-12-04 Oreal Composition photoprotectrice fluide aqueuse a base d'un polymere polyamide a terminaison amide tertiaire.
FR2925326B1 (fr) * 2007-12-21 2010-02-26 Vincience Utilisation d'un hydrolysat de mais en tant que principe actif activateur de la synthese des aquaporines
FR2925327A1 (fr) * 2007-12-21 2009-06-26 Vincience Sa Utilisation d'un hydrolysat d'epeautre en tant que principe actif activateur de la synthese des aquaporines
FR2925330B1 (fr) * 2007-12-21 2010-04-09 Vincience Utilisation d'un hydrolysat de pomme de terre en tant que principe actif activateur de la synthese des aquaporines
FR2925325B1 (fr) 2007-12-21 2010-02-26 Vincience Utilisation d'un hydrolysat de colza en tant que principe actif activateur de la synthese des aquaporines
FR2927254B1 (fr) 2008-02-12 2010-03-26 Lesaffre & Cie Utilisation de substances actives naturelles dans des compositions cosmetiques ou therapeutiques

Also Published As

Publication number Publication date
CN102459310B (zh) 2016-08-03
US20120094920A1 (en) 2012-04-19
US8674072B2 (en) 2014-03-18
FR2944526B1 (fr) 2013-05-10
CN102459310A (zh) 2012-05-16
WO2010119191A1 (fr) 2010-10-21
EP2419438A1 (de) 2012-02-22
ES2549392T3 (es) 2015-10-27
FR2944526A1 (fr) 2010-10-22
JP2012524049A (ja) 2012-10-11

Similar Documents

Publication Publication Date Title
EP2419438B1 (de) Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung
EP2515840B1 (de) Kosmetische und/oder pharmazeutische zusammensetzung enthaltend einen johannisbrotbaum-extrakt als aktiven inhaltsstoff zur aktivierung der aquaporin-expression
EP2421884B1 (de) Peptidhydrolysat als proteasomaktivator und zusammensetzungen, die dieses enthalten
EP2182964B1 (de) Verwendung eines flachsextrakts in einer kosmetischer oder dermatologischer zusammensetzung zur aktivierung von cytochrom c
FR2915383A1 (fr) Utilisation d'un principe actif issu du riz (oryza sativa l.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2915380A1 (fr) Utilisateur d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a activer le cytochrome c
FR2915384A1 (fr) Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2915381A1 (fr) Utilisation d'un principe actif issu du soja (glycine max l) pour preparer une composition destinee a activer le cytochrome c
FR2915382A1 (fr) Utilisation d'un principe actif issu du mais (zea mays l) pour preparer une composition destinee a activer le cytochrome c
FR2915379A1 (fr) Utilisation d'un principe actif issu du riz (oryza sativa l) pour preparer une composition destinee a proteger les mitochondries
FR2915378A1 (fr) Utilisation d'un principe actif issu du soja (glycine max l.) pour preparer une composition destinee a proteger les mitochondries
FR2925330A1 (fr) Utilisation d'un hydrolysat de pomme de terre en tant que principe actif activateur de la synthese des aquaporines
EP2421885B1 (de) Bleichendes peptidhydrolysat als proteasomaktivator und zusammensetzungen, die dieses enthalten
FR2925331A1 (fr) Utilisation d'un hydrolysat de feve en tant que principe actif activateur de la synthese des aquaporines
EP2419439B1 (de) Ein linderndes peptidisches hydrolysat enthaltende kosmetische und/oder pharmazeutische zusammensetzung
FR2938765A1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur des proteines sirt
FR2944527A1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique capable de renforcer la fonction barriere
FR2944446A1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat peptidique apaisant
FR2915377A1 (fr) Utilisation d'un principe actif issu de l'amarante (amaranthus) pour preparer une composition destinee a proteger les mitochondries
FR2938766A1 (fr) Composition cosmetique et/ou pharmaceutique comprenant un hydrolysat de feuille de vigne (vitis vinifera l.) en tant que principe actif activateur de l'aconitase et protecteur des mitochondries
FR2915385A1 (fr) Utilisation d'un principe actif issu de l'amarante (amaranthus) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2944795A1 (fr) Hydrolysats peptidiques activateurs du proteasome et compositions les contenant
FR2994656A1 (fr) Extrait de lin et composition cosmetique comprenant ledit extrait pour augmenter le niveau de coenzyme q10 intracellulaire
FR2944796A1 (fr) Hydrolysats peptidiques eclaircissants activateurs du proteasome et compositions les contenant
FR2925328A1 (fr) Utilisation d'un hydrolysat de kamut en tant que principe actif activateur de la synthese des aquaporines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20121030

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/08 20060101ALI20141127BHEP

Ipc: C07K 14/415 20060101ALI20141127BHEP

Ipc: C07K 5/103 20060101AFI20141127BHEP

Ipc: A61Q 17/04 20060101ALI20141127BHEP

Ipc: A61K 8/97 20060101ALI20141127BHEP

Ipc: A61K 38/01 20060101ALI20141127BHEP

Ipc: A61K 8/64 20060101ALI20141127BHEP

Ipc: C07K 7/06 20060101ALI20141127BHEP

Ipc: A61Q 19/00 20060101ALI20141127BHEP

Ipc: A61Q 19/08 20060101ALI20141127BHEP

Ipc: A61K 38/07 20060101ALI20141127BHEP

Ipc: A61P 17/00 20060101ALI20141127BHEP

Ipc: A61Q 17/00 20060101ALI20141127BHEP

Ipc: C07K 14/395 20060101ALI20141127BHEP

INTG Intention to grant announced

Effective date: 20141212

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISP INVESTMENTS INC.

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150313

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 736730

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010025900

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: DR. LUSUARDI AG, CH

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2549392

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20151027

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 736730

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150715

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151015

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151116

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010025900

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

26N No opposition filed

Effective date: 20160418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160415

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100415

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150715

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20180503

Year of fee payment: 9

Ref country code: CH

Payment date: 20180502

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20180625

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190415

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20200831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190416

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240425

Year of fee payment: 15